Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Pargellis

Showing results (31-40 of 36) with videos related to

Pageof 4
Sort By:
You have reached the last page of results.This site can display upto 36 results.
Journal of Medicinal Chemistry|October 17, 2003
Structure-activity relationships of the p38alpha MAP kinase inhibitor 1-(5-tert-butyl-2-p-tolyl-2H-pyrazol-3-yl)-3-[4-(2-morpholin-4-yl-ethoxy)naph- thalen-1-yl]urea (BIRB 796)John Regan, Alison Capolino, Pier F Cirillo, et al.
Bioorganic & Medicinal Chemistry Letters|June 15, 2007
New modifications to the area of pyrazole-naphthyl urea based p38 MAP kinase inhibitors that bind to the adenine/ATP siteNeil Moss, Steffen Breitfelder, Raj Betageri, et al.
Bioorganic & Medicinal Chemistry Letters|June 20, 2007
The discovery of carboline analogs as potent MAPKAP-K2 inhibitorsJiang-Ping Wu, Ji Wang, Asitha Abeywardane, et al.
Bioorganic & Medicinal Chemistry Letters|January 29, 2008
Pyrazinoindolone inhibitors of MAPKAP-K2D R Goldberg, Y Choi, D Cogan, et al.
Bioorganic & Medicinal Chemistry Letters|April 10, 2009
Discovery and characterization of the N-phenyl-N'-naphthylurea class of p38 kinase inhibitorsPier F Cirillo, Eugene R Hickey, Neil Moss, et al.
Journal of Medicinal Chemistry|July 31, 2007
Discovery and optimization of p38 inhibitors via computer-assisted drug designDaniel R Goldberg, Ming-Hong Hao, Kevin C Qian, et al.
Pageof 4

Showing results (31-40 of 36) with videos related to

Sort By:
Pageof 4
You have reached the last page of results.This site can display upto 36 results.
Journal of Medicinal Chemistry|October 17, 2003
Structure-activity relationships of the p38alpha MAP kinase inhibitor 1-(5-tert-butyl-2-p-tolyl-2H-pyrazol-3-yl)-3-[4-(2-morpholin-4-yl-ethoxy)naph- thalen-1-yl]urea (BIRB 796)John Regan, Alison Capolino, Pier F Cirillo, et al.
Bioorganic & Medicinal Chemistry Letters|June 15, 2007
New modifications to the area of pyrazole-naphthyl urea based p38 MAP kinase inhibitors that bind to the adenine/ATP siteNeil Moss, Steffen Breitfelder, Raj Betageri, et al.
Bioorganic & Medicinal Chemistry Letters|June 20, 2007
The discovery of carboline analogs as potent MAPKAP-K2 inhibitorsJiang-Ping Wu, Ji Wang, Asitha Abeywardane, et al.
Bioorganic & Medicinal Chemistry Letters|January 29, 2008
Pyrazinoindolone inhibitors of MAPKAP-K2D R Goldberg, Y Choi, D Cogan, et al.
Bioorganic & Medicinal Chemistry Letters|April 10, 2009
Discovery and characterization of the N-phenyl-N'-naphthylurea class of p38 kinase inhibitorsPier F Cirillo, Eugene R Hickey, Neil Moss, et al.
Journal of Medicinal Chemistry|July 31, 2007
Discovery and optimization of p38 inhibitors via computer-assisted drug designDaniel R Goldberg, Ming-Hong Hao, Kevin C Qian, et al.
Pageof 4